Cytek Biosciences enters its third-quarter report with a demand story that has clearly turned and a profit story that has not. Last quarter, management raised the floor of its full-year revenue outlook on the back of a strong rebound in the US and China. In the same breath, it walked its adjusted EBITDA goal back from positive to roughly break-even. The stock has since jumped nearly 35% while the S&P 500 went nowhere. That makes this report less about whether the recovery is real and more about whether it can start showing up below the revenue line.
The Street is not asking for much on the top line. Consensus calls for revenue of $52.9 million, only about 1% above the year-ago $52.3 million. That is a notable slowdown from the 6% growth posted in each of the first two quarters. Analysts see a loss of 8 cents a share, double the 4-cent loss a year earlier and roughly in line with the 9-cent loss last quarter. Full-year consensus of about $209.4 million sits almost exactly at the midpoint of management's $207 million to $212 million range. With $92.2 million booked in the first half, the guidance implies a heavily back-end-loaded year. If Cytek meets the third-quarter number, it still needs something like $62 million to $67 million in the fourth quarter, against $62.1 million a year ago. A soft third quarter would push even more weight onto the holiday-quarter budget flush.
The modest revenue bar looks beatable if last quarter's geographic trends hold. The US delivered a record second quarter, up 18%, following a 32% jump in the first quarter. China swung from contraction to strong double-digit growth. Europe is the counterweight. It fell 8% last quarter on government budget pressure, while academic and government demand outside the US dropped about 12%. One nuance helps here: European revenue collapsed 28% in the year-ago third quarter, so the comparison is unusually easy. Even stabilization there could lift reported growth meaningfully above consensus. Continued erosion would suggest the weakness is structural rather than cyclical.
Product and recurring revenue offer the next layer of evidence. Management introduced two new catalysts last quarter. The first is Borealis, a 60-color, seven-laser spectral analyzer that early-access customers reportedly received very well. The second is an expanded Aurora Evo configuration aimed at high-throughput biopharma and contract research labs. Any color on order activity, funnel building or early shipments would help show whether these launches can carry growth into next year. Service revenue, up 10% last quarter with margins of 56%, has grown at a double-digit pace for four straight calls. Recurring revenue now accounts for 35% of trailing sales, and keeping that streak intact matters for valuation.
Margins are where the narrative is most vulnerable. Last quarter's 59% gross margin was flattered by a one-time $2.8 million tariff refund. Excluding it, product margin slipped to 52% from 53%. Without that refund, the third quarter will reveal the true run rate. G&A also rose 24% on patent litigation and severance, and the reorganization into three customer-aligned business units began operating this quarter. Investors deserve evidence that these costs are peaking rather than becoming permanent. A third-quarter EBITDA figure near break-even, rather than another loss like the $1.5 million deficit last quarter, would make the softened full-year target look credible.
Sentiment has warmed, moving from 11.5% bearish ahead of last quarter to just 3.2% bearish now. The shares sit at $5.89, well above the 200-day average of $4.65 and in the upper part of their post-earnings range. They trade about 5% below the $6.21 high, a range that sits entirely above the prior quarter's peak. That rerating raises the stakes. Revenue that merely matches a low bar may not be enough. To keep the rally intact, Cytek likely needs to show that US and China strength is durable, that Europe has bottomed, and that underlying gross margin and spending discipline can deliver break-even profitability without one-time help.